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Introduction: Pre-eclampsia is a pregnancy-speciﬁc disorder and characterized by reduced trophoblast
invasion and reduced spiral artery remodeling in the ﬁrst trimester placenta. A polymorphism located in
the promoter region of ACVR2A (rs1424954 (A > G)) has previously been shown to be signiﬁcantly
associated with pre-eclampsia.
Methods: The effects of this variant on ACVR2A expression and its function in the Activin-A signaling
pathway were studied by transfections in SGHPL-5 extravillous trophoblasts followed by qRT-PCR.
Results: Here we show that the ACVR2A promoter susceptibility variant causes a downregulation of
ACVR2A expression. We also provide evidence for transcription of a so-called PROMPT (PROMoter-uP-
stream-Transcript) in the opposite direction of ACVR2A, containing the polymorphism, and down-
regulated when the susceptibility allele is carried, which either shares the same promoter as ACVR2A or is
a non-coding RNA that is able to enhance ACVR2A transcription. Furthermore, when the effect of the
susceptibility variant is mimicked by knockdown of ACVR2A, physiologic concentrations of Activin-A
cause a reduction in NODAL mRNA expression in the SGHPL-5 trophoblasts, indicative of a protective
effect as reduction in NODAL expression is associated with an increase in trophoblast invasion. However,
at pathologic levels of Activin-A, as found in pre-eclampsia, this effect is no longer seen, and we show
this is potentially caused by a lack of downregulation of ACVR2B.
Discussion: The combined data suggest a double hit phenomenon in which the ﬁrst hit, the promoter
variant, together with the second hit, pathological levels of Activin-A, lead to high levels of NODAL,
associated with reduced trophoblast invasion and observed in pre-eclamptic placentas.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Pre-eclampsia (PE) is a potentially life threatening disease of
human pregnancy affecting 2e8% of all pregnancies which remits
after delivery [1], thus making the placenta central in PE. During PE,
migration properties of the placental trophoblast cells are thought
to be impaired, leading to insufﬁcient invasion of the trophoblasts
into the maternal decidua causing improper remodeling of spiral
arteries.
In two large positional candidate gene-based association studies
involving the Norwegian and Australian populations, ACVR2A wasmistry, VU University Medical
etherlands. Tel.: þ31 20 444identiﬁed on chromosome 2q22 as a candidate for a common
susceptibility gene for pre-eclampsia [2e4]. By measuring the
squared value of the pairwise correlation among intragenic geno-
types (r2) with the observed patterns of LD referred to as iso-
correlated redundant variant (IRV) sets, three very strong (r2 > 0.7)
IRV sets were seen in the Norwegian population-based study
(HUNT study). One of them, IRV1 deﬁned by seven SNPs
(rs1424954, rs1014064, rs2161983, rs2288190, rs10497025,
rs3768687 and rs3764955) exhibited an OR > 1, indicating that pre-
eclamptic women are more likely than control women to carry the
major allele at these loci [2,3].
We decided to functionally test the allele-dependency of one of
these, i.e. rs1424954 within IRV1 of the ACVR2A gene for several
reasons. i. This SNP showed the strongest association in the inde-
pendent Australian study as well [2]. ii. The association of pre-
eclampsia with rs1424954 has been replicated in the Brazilian
population [5]. iii. rs1424954 (chr2:148600794) is an upstream
Fig. 1. ACVR2A exon 1 mRNA expression. RT-qPCR measuring ACVR2A exon 1 tran-
scription in SGHPL-5 cells after transfection with plasmids containing the ACVR2A
promoter and ACVR2A exon 1 with either the wildtype allele (A) or the susceptibility
allele (G). Bars are mean ± SEM from four experiments, * indicates P < 0.05.
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at 177 bp upstream of the transcription start site (chr2:148602564).
This makes a functional effect likely. iv. The expression patterns of
the receptor, ACVR2A, and its ligand, Activin-A in normal and
abnormal (pre-eclamptic) placentation [6e9], the upregulation of
Activin-A in serum of pre-eclamptic mothers [10e13], along with
experimental evidence in cell culture model systems (SGHPL5,
HTR8/SVneo) [14e18] indicate the existence of a functional
pathway in the early placenta with interaction between maternal
decidua and fetal trophoblast. This pathway involves at least one
receptor (ACVR2A) and two ligands (Activin-A and Nodal) as we
recently showed that Nodal knockdown in the maternal decidua
upregulates NODAL mRNA expression in fetal extravillous tropho-
blast cells, potentially via upregulation of Activin-A in the maternal
decidua [14]. Furthermore, invasion potential of trophoblast cells is
inhibited by Nodal with placentas of pre-eclamptic patients
showing upregulated Nodal expression [19]. Finally, high doses of
Activin-A in human trophoblasts cells (HTR8/SVneo) have been
shown to upregulate Nodal expression [17], while knockdown of
ACVR2A in HTR8/SVneo cells showed an invasion promoting effect
with ACVR2A protein signiﬁcantly upregulated in term PE pla-
centas [18].
We therefore tested the functional effect and allele-dependency
of rs1424954 in this Activin A- ACVR2A-Nodal pathway to see if this
could explain the association between the susceptibility allele of
rs1424954 and pre-eclampsia.
2. Material and methods
2.1. Construction of plasmids containing the ACVR2A promoter region and exon 1
A 2434 bp DNA fragment (chr2: 148600343-148602776) containing the ACVR2A
promoter region (HG_KWN:35322) (MPromDB) and ACVR2A exon 1 was cloned into
pF12A-RM-ﬂexi vector (Promega) according to the manufacturer's instructions,
using the following primers (Forward: 50-TCT TCC ATT CCA GAA CCG TTA-30 and
Reverse: 50-CTG AAG AAC AGG AGA TAA GAA AGA C-30). The rs1424954 variant was
introduced by using the Quickchange XL site-directed mutagenesis kit (Stratagene)
according to manufacturer's instructions. Integrity and orientation were veriﬁed by
sequencing.
2.2. Cell culture and transfection
For cell culture, 2*105 SGHPL-5 cells, kindly provided by Dr Judith Cartwright, St
George's University of London, UK, were plated in 12 well plates. Cells were cultured
in IMDM medium containing fetal bovine serum (FBS) at 37 C under 5% CO2.
Plasmids containing the ACVR2A promoter region and exon 1 with wildtype allele
(A) or susceptibility allele (G) were transfected into cells using FuGENE HD Trans-
fection Reagent according to manufacturer's instructions (Promega). Forty-eight
hours after transfection, RNA was isolated. Four independent transfection experi-
ments were performed in triplicate.
siRNA transfection experiments were performed by using lipofectamine RNAi-
MAX (Invitrogen) in combination with 15 pmol ACVR2A siRNAs (Qiagen ﬂexitube
gene solution) or AllStars Negative control siRNAs (Qiagen) in media supplemented
with 0.1% FBS. After 8 h, recombinant Activin-A (Life technologies) was added at four
different ﬁnal concentrations (0, 5, 50 and 100 ng/ml). After 48 h, RNA was isolated.
Three independent transfection experiments were performed in triplicate.
2.3. RNA isolation and quantitative RT-PCR
RNA isolation was performed using the RNeasy kit (Qiagen) including on-
column DNase treatment. For plasmid transfections, RNA was reverse transcribed
to cDNA (Superscript III First strand synthesis system, Invitrogen) using a primer
speciﬁc for exon 1 of ACVR2A. eRT reactions were performed to monitor and, if
necessary, correct for transfection efﬁciency. Subsequently quantitative real time
PCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems)
with ACVR2A forward (50-CGA GAA CTT CCT CCG GAT T-30) and reverse primer (50-
CAA ACG CCA ACT TTG CAG-30). For quantiﬁcation of PROMPT, PROMPT speciﬁc
primers (forward: 50-CCA AAA CTT TGT AGA GTA CAT TAA CAG-30 , reverse: 50-TCC
AGC ACC CAG AAG TAT CA-30) and probe (50-TGA CTA AGG GAT GAC TGC CTT TCT CT-
30) were designed and strand-speciﬁc RT-qPCR was performed. For siRNA trans-
fections, quantitative RT-PCR was performed using Taqman RNA-to-Ct Kit (Applied
Biosystems) in combination with gene expression assays (Applied Biosystems) for
ACVR2A (for conﬁrmation of knockdown, see Supplementary Fig. 1), ACVR2B and
NODAL. For all quantitative RT-PCRs normalization was done by measuring GAPDH.2.4. Data analysis
All data were analyzed by calculating the delta Ct values and corrected for
transfection efﬁciency. Relative expression levels are expressed as mean ± SEM
unless stated otherwise. Statistical analysis was done by Student's t-tests using
Prism 5.0c (GraphPad Prism, San Diego, CA, USA). All graphs are based on the
combined data of independent transfections.3. Results
3.1. Effect of the rs1424954 promoter polymorphism on ACVR2A
exon 1 expression
To investigate the effect of the SNP located in the promoter re-
gion of ACVR2A, we cloned the promoter region containing the
wildtype (A) and susceptibility (G) allele together with ACVR2A
exon 1 in a vector containing an inactive promoter. These con-
structs were transiently transfected in SGHPL-5 cells, representa-
tive of ﬁrst trimester extravillous trophoblast cells, after which RNA
was isolated and analyzed by quantitative RT-PCR measuring exon
1 expression of ACVR2A (NM_001616). This showed that the pro-
moter containing the G allele gave signiﬁcantly lower expression
levels for exon 1 than the A allele (Fig. 1).
This reduced expression of ACVR2Awith the susceptibility allele
present in the promoter might be caused by reduced binding of a
transcription factor to regulatory sequences controlling transcrip-
tion initiation. Another possibility that could cause reduced
expression is the fact that the SNP is located in a potential PROMPT
(PROMoter uPstream Transcript) regulating ACVR2A gene tran-
scription [20]. Ongoing high-coverage RNA-sequencing experi-
ments have conﬁrmed the presence and size of a PROMPT
transcript. For this, paired-end sequencing (2  125 bp)
(HiSeq2500, version 4 chemistry) was done of cDNA libraries
generated from polyA þ mRNA of SGHPL-5 cells. Mapping with
transcriptome reconstruction was done with the Tuxedo pipeline
under RABT assembly conditions. By this, a PROMPT transcript
upstream of ACVR2A was identiﬁed and found to correlate exactly
with the BE044444 and BM709416 expressed sequence tags
(GRCh37/hg19 assembly) providing the 5’- and 3’-end boundaries,
respectively, and forming a transcript of 1059 bases. To validate if
indeed a PROMPT was expressed, we ﬁrst applied strand-speciﬁc
quantitative RT-PCR to determine its normal endogenous pres-
ence as tested in untransfected cells. This conﬁrmed the presence of
a transcript transcribed from the opposite strand as ACVR2A
(Fig. 2A). After transfection of the constructs consisting of the
promoter region, ACVR2A exon 1, but which also include the
PROMPT region, PROMPT expression showed the same directional
Fig. 2. Expression of PROMPT in the ACVR2A promoter. (A) Levels of PROMPT mRNA measured by strand speciﬁc RT-qPCR conﬁrmed the antisense direction of PROMPT tran-
scription. (B) PROMPT expression levels after transfection with plasmids containing the ACVR2A promoter and ACVR2A exon 1 with either the wildtype allele (A) or the susceptibility
allele (G).Bars are mean ± SEM from four experiments, * indicates P < 0.05.
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expression of the PROMPT transcript than the cells transfectedwith
the susceptibility allele carrying construct (Fig. 2B).3.2. Only pathological levels of Activin-A enhance nodal expression
after ACVR2A knockdown
To explore the role of ACVR2A in the Activin-A signaling pathway
in trophoblasts, SGHPL-5 cells were transiently transfected with
siRNAs directed against ACVR2A or negative control siRNAs fol-
lowed by treatment with recombinant Activin-A at four different
concentrations, i.e. 0, 5, 50 and 100 ng/ml, where 5 ng/ml repre-
sents physiological concentrations, while 50e100 ng/ml are found
in pathologic pregnancies. After 48 h of Activin-A treatment, a
dose-dependent effect of Activin-A on Nodal mRNA expression
levels was observed (Fig. 3), where an increase in Activin-A con-
centration leads to an increase in NODAL expression, consistent
with earlier observations [19]. After knockdown of ACVR2A, the
NODAL expression levels upon physiologic concentrations of
Activin-A where lower than in the control situation, while at
pathological concentrations this difference was no longer seen
(Fig. 3). This indicates that at pathological concentrations inFig. 3. NODAL expression after Activin-A treatment in combination with ACVR2A
knockdown. NODAL mRNA expression levels increase after Activin-A treatment, while
ACVR2A knockdown causes reduced levels of Nodal at physiological concentrations
(5 ng/ml), while at pathological concentrations (50e100 ng/ml) similar levels of Nodal
are found as seen in the control situation. Points are mean ± SEM from three exper-
iments showing p-values > 0.1 between control and ACVR2A knockdown for all
Activin-A concentrations except for 5 ng/ml.combination with reduced availability of the ACVR2A receptor
another receptor apparently is able to take over to cause this effect.
The only receptor qualifying for this is ACVR2B being the only other
type II receptor that can bind Activin-A. We therefore investigated
the mRNA expression levels of ACVR2B in our samples. Interest-
ingly, in the control situation, ACVR2B expression is signiﬁcantly
downregulated when Activin-A concentrations go from physiologic
to pathologic. In contrast, in the ACVR2A knockdown samples
ACVR2B levels are lower at physiologic concentration but do not
further decrease under pathologic conditions (Fig. 4), indicating
that the ACVR2B receptor might be responsible for the effects
observed.4. Discussion
In this study, we show the effect of the rs1424954 SNP located in
the promoter region of ACVR2A on ACVR2A expression levels in
trophoblast cells. We found that the pre-eclampsia susceptibility
allele causes a decrease in ACVR2A expression. We further show
that bymimicking this effect using siRNAs directed against ACVR2A,
its ligand Activin-A effects on NODAL expression in trophoblasts are
reduced under physiological concentrations of Activin-A, while at
pathologic concentrations of Activin-A this effect disappears.
Finally, we show that the latter observation of Nodal expression is
potentially caused by a lack of downregulation of the ACVR2B re-
ceptor in these samples.Fig. 4. ACVR2B mRNA expression after Activin-A treatment in combination with
ACVR2A knockdown. ACVR2B mRNA expression levels decrease at pathological Activin-
A concentrations in the control situation, while knockdown of ACVR2A leads to lower
ACVR2B levels at physiologic concentration which remain constant at pathologic levels.
Bars are mean ± SEM from three experiments, * indicates P < 0.05.
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NODAL expression in fetal trophoblasts cells, potentially via upre-
gulation of Activin-A in the maternal decidua [14]. In this study we
show that the ACVR2A SNP associated with pre-eclampsia affects
this signaling cascade. At physiologic Activin-A concentrations the
susceptibility allele is protective, i.e. the levels of Nodal are reduced,
associated with an increase in trophoblast invasion and inversely
correlated with pre-eclampsia [19]. However, at pathological con-
centrations of Activin-A the protective effect of the polymorphism
is no longer present which seems to be caused by a lack of ACVR2B
receptor downregulation. Interestingly, the ACVR2B receptor has a
3-4 times higher afﬁnity for Activin-A than the ACVR2A receptor
[21], indicating that when downregulation fails at pathological
levels of Activin-A due to reduced expression of ACVR2A, the effects
on Nodal expression might even worsen further, i.e. even more
Nodal expression. The combined data presented in this study
therefore suggest a double hit phenomenon in which the ﬁrst hit,
the SNP, even acts protectively, but, together with the second hit
being the pre-eclampsia associated pathological levels of Activin-A,
leads to high levels of Nodal as found to reduce trophoblast inva-
sion and as seen in pre-eclamptic placentas [19]. Fig. 5 shows the
proposed model by which Activin-A levels signal through ACVR2A
and ACVR2B receptors regulating Nodal in extravillous trophoblasts.
The observation that the susceptibility allele present in the
promoter reduces the expression of ACVR2A might be caused by
reduced binding of a transcription factor or the transcription
initiation complex. We also investigated another possibility as an
unspliced EST was present at the promoter and which would also
contain the SNP. We investigated if the EST might function as a
PROMPT (PROMoter uPstream Transcript) regulating ACVR2A gene
transcription [20]. We conﬁrmed transcription of this transcript,
transcribed in the opposite direction of ACVR2A. Furthermore, after
transfection of the promoter-exon 1 constructs, the transfected
wildtype construct showed higher expression of the PROMPT thanFig. 5. Proposed model of Nodal regulation by Activin-A signaling through ACVR2A and
ACVR2B receptors in extravillous trophoblasts. At physiologic Activin-A concentrations
the susceptibility allele, yielding lower ACVR2A levels, might be protective, i.e. the
levels of Nodal are reduced which is associated with an increase in trophoblast inva-
sion and inversely correlated with pre-eclampsia. At pathological concentrations of
Activin-A the protective effect of the polymorphism is no longer present which seems
to be caused by a lack of ACVR2B receptor downregulation.the SNP carrying construct, similar as seen for ACVR2A expression
itself. Based on these ﬁndings, there are two possibilities on how
the rs1424954 SNP might inﬂuence the transcription of ACVR2A.
The ﬁrst option is that both ACVR2A and PROMPT transcripts share
the same promoter inwhich the susceptibility allele causes reduced
binding of the transcription unit. Based on more recent knowledge
regarding the common occurrence of upstream antisense tran-
scription initiation [22], it is also very likely that the PROMPT
functions as a non-coding RNA that is able to enhance ACVR2A
transcription in cis, inwhich the PROMPTcarrying the susceptibility
allele has a reduced expression and hence is less efﬁcient.
To conclude, we here show that the pre-eclampsia susceptibility
allele (G) of the ACVR2A promoter SNP (rs1424954) causes a
downregulation of ACVR2A transcription in trophoblast cells.
Downregulation of this Activin-A receptor at physiological levels of
Activin-A seems to be protective as it causes reduced NODAL
expressionwhich is associatedwith increased trophoblast invasion.
However, at pathological levels of Activin-A this effect on NODAL is
no longer there, potentially caused by a lack in ACVR2B
downregulation.
Conﬂict of interest statement
The authors declare that the research was conducted in the
absence of any commercial or ﬁnancial relationships that could be
construed as a potential conﬂict of interest.Acknowledgments
This work was supported by a grant from the Institute for Car-
diovascular Research of the VU University (ICaR-VU) in Amsterdam,
the Netherlands.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.placenta.2015.01.010.References
[1] Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol
2009;33(3):130e7.
[2] Fitzpatrick E, Johnson MP, Dyer TD, Forrest S, Elliott K, Blangero J, et al. Genetic
association of the activin A receptor gene (ACVR2A) and pre-eclampsia. Mol
Hum Reprod 2009;15:195e204.
[3] Roten LT, Johnson MP, Forsmo S, Fitzpatrick E, Dyer TD, Brennecke SP, et al.
Association between the candidate susceptibility gene ACVR2A on chromo-
some 2q22 and pre-eclampsia in a large Norwegian population-based study
(the HUNT study). Eur J Hum Genet 2009;17:250e7.
[4] Moses EK, Fitzpatrick E, Freed KA, Dyer TD, Forrest S, Elliott K, et al. Objective
prioritization of positional candidate genes at a quantitative trait locus for
pre-eclampsia on 2q22. Mol Hum Reprod 2006;12:505e12.
[5] Ferreira LC, Gomes CM, Araújo ACP, Bezerra PF, Duggal P. Jeronimo SBM As-
sociation between ACVR2A and early onset preeclampsia: replication study in
a Northeastern Brazilian population. Placenta 2015;36(2):186e90.
[6] Peng C, Huang THJ, Jeung EB, Donaldson CJ, Vale WW, Leung PCK. Expression
of the type II activin receptor gene in the human placenta. Endocrinology
1993;133:3046e9.
[7] Schneider-Kolsky ME, Manuelpillai U, Waldron K, Dole A, Wallace EM. The
distribution of activin and activin receptors in gestational tissues across hu-
man pregnancy and during labour. Placenta 2002;23(4):294e302.
[8] Caniggia I, Lye SJ, Cross JC. Activin is a local regulator of human cytotropho-
blast cell differentiation. Endocrinology 1997;138:3976e86.
[9] Jones RL, Stoikos C, Findlay JK, Salamonsen LA. TGF-beta superfamily
expression and actions in the endometrium and placenta. Reproduction
2006;132:217e32.
[10] Grobman WA, Wang EY. Serum levels of activin A and inhibin A and the
subsequent development of preeclampsia. Obstet Gynecol 2000;96:390e4.
[11] Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, et al.
Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia.
Hum Reprod 2000;15:1640e5.
H.K. Thulluru et al. / Placenta 36 (2015) 345e349 349[12] Zwahlen M, Gerber S, Bersinger NA. First trimester markers for pre-eclampsia:
placental vs. non-placental protein serum levels. Gynecol Obstet Invest
2007;63:15e21.
[13] Akolekar R, Etchegaray A, Zhou Y. Maternal serum activin a at 11-13 weeks of
gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther 2009;25:
320e7.
[14] Thulluru HK, Park C, Dufort D, Kleiverda G, Oudejans C, van Dijk M. Maternal
nodal inversely affects NODAL and STOX1 expression in the fetal placenta.
Front Genet 2013;4:170.
[15] Munir S, Xu G, Wu Y, Yang B, Lala PK, Peng C. Nodal and ALK7 inhibit pro-
liferation and induce apoptosis in human trophoblast cells. J Biol Chem
2010;279:31277e86.
[16] Giguere Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al.
Combining biochemical and ultrasonographic markers in predicting pre-
eclampsia: a systematic review. Clin Chem 2010;56:361e75.
[17] Yu L, Li D, Liao QP, Yang HX, Cao B, Fu G, et al. High levels of activin a detected
in pre-eclamptic placenta induce trophoblast cell apoptosis by promoting
nodal signaling. J Clin Endocrinol Metab 2012;97:1370e9.[18] Bai Y, Yang W, Yang HX, Liao Q, Ye G, Fu G, et al. Downregulated miR-195
detected in preeclamptic placenta affects trophoblast cell invasion via
modulating ActRIIA expression. PLoS One 2012;7(6).
[19] Nadeem L, Munir S, Fu G, Dunk C, Baczyk D, Caniggia I, et al. Nodal signals
through activin receptor-like kinase 7 to inhibit trophoblast migration and
invasion: implication in the pathogenesis of pre-eclampsia. Am J Pathol
2011;178:1177e89.
[20] Preker P, Almvig K, Christensen MS, Valen E, Mapendano CK, Sandelin A, et al.
PROMoter uPstream transcripts share characteristics with mRNAs and are
produced upstream of all three major types of mammalian promoters. Nucleic
Acids Res 2011;39:7179e93.
[21] Feijen A, Goumans MJ, van den Eijnden-van Raaij AJ. Expression of activin
subunits, activin receptors and follistatin in postimplantation mouse embryos
suggests speciﬁc developmental functions for different activins. Development
1994;120:3621e37.
[22] Pelechano V, Steinmetz LM. Gene regulation by antisense transcription. Nat
Rev Genet 2013;14:880e93.
